Research programme: axon regeneration therapies - Alseres Pharmaceuticals

Drug Profile

Research programme: axon regeneration therapies - Alseres Pharmaceuticals

Alternative Names: ALSE-100; CBP-15 calcium-binding protein; MDP14; OCM protein; Oncomodulin

Latest Information Update: 19 Jan 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Childrens Hospital Boston
  • Developer Alseres Pharmaceuticals
  • Class Calcium binding proteins
  • Mechanism of Action Neuron stimulants; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Brain injuries; Cardiomyopathies; Eye-Disorders; Spinal cord injuries

Most Recent Events

  • 19 Nov 2008 Pharmacodynamics data from a preclinical trial in Eye disorders presented at the the 38th Annual Meeting for the Society of Neuroscience (SfN-2008)
  • 26 May 2008 The Regenerative Therapeutics programme is available for licensing (http://www.alseres.com)
  • 08 Jun 2007 Boston Life Sciences is now called Alseres Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top